Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate

MT Newswires Live11-09

Fate Therapeutics (FATE) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.

The data "support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells," Bob Valamehr, head of research and development at Fate, said in a statement.

Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.

FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel "Sword & Shield" technology "to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors," the company said.

Price: 2.47, Change: +0.05, Percent Change: +2.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482451088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482451088","market":"hk","top_or_hot":-1,"title":"Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate","media":"MT Newswires Live","content":"<html><body><p> Fate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (FATE) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.</p><p>The data \"support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells,\" Bob Valamehr, head of research and development at Fate, said in a statement.</p><p>Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.</p><p>FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel \"Sword &amp; Shield\" technology \"to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors,\" the company said.</p><p>Price: 2.47, Change: +0.05, Percent Change: +2.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 05:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fate Therapeutics (FATE) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.The data \"...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4230","symbol_name":"旅客陆运","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482451088","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482451088","pubTimestamp":1731102824,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fate Therapeutics  said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.The data \"support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells,\" Bob Valamehr, head of research and development at Fate, said in a statement.Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel \"Sword & Shield\" technology \"to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors,\" the company said.Price: 2.47, Change: +0.05, Percent Change: +2.07","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4230":"旅客陆运","BK4139":"生物科技","BK4022":"陆运","FATE":"Fate Therapeutics Inc","CAR":"安飞士"},"translate_title":"Fate Therapeutics报告癌症治疗候选药物的积极临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FATE":1,"CAR":0.7},"content_text":"Fate Therapeutics (FATE) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.The data \"support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells,\" Bob Valamehr, head of research and development at Fate, said in a statement.Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel \"Sword & Shield\" technology \"to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors,\" the company said.Price: 2.47, Change: +0.05, Percent Change: +2.07","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482451088"}